ストックスクリーナーアプリを入手
0.9463
11.57%
-0.1238
Rani Therapeutics Holdings Inc (RANI) 最新ニュース
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics to raise $20M in registered direct offering - MSN
Sovereign wealth fund leads $20M raise for oral drug delivery firm - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - The Manila Times
Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down - Moomoo
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics reports Q1 EPS (4c), consensus (5c) - TipRanks
Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI - Moomoo
Rani Therapeutics CFO to depart, reports Q1 results - Investing.com UK
Rani Therapeutics CFO to depart, reports Q1 results By Investing.com - Investing.com South Africa
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice - TipRanks
Rani Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RANI: Q1 2026 saw clinical progress, leadership changes, and a reduced net loss year-over-year - TradingView
Rani Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Rani Therapeutics (RANI) posts Q1 2026 loss with new Chugai revenue and $43M cash - Stock Titan
Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition - Stock Titan
Oral biologics firm Rani trims Q1 loss; CFO to step down - Stock Titan
Rani Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
SymBiosis Capital holds 4.43M RANI shares, reports 4.4% stake (RANI) - Stock Titan
TradingKey - TradingKey
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - The Manila Times
Rani Therapeutics (NASDAQ:RANI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Rani Therapeutics Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year - Yahoo Finance
MSN Money - MSN
Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday - MarketBeat
RANI Technical Analysis | Trend, Signals & Chart Patterns | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):